A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma

Ji Eun Jang, Yu Ri Kim, Soo Jeong Kim, Hyunsoo Cho, Haerim Chung, Jung Yeon Lee, Hyunsung Park, Yundeok Kim, June Won Cheong, Yoo Hong Min, Jinseok Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose Primary central nervous system lymphoma (PCNSL) is an aggressive and rare extranodal non-Hodgkin lymphoma (NHL). Absolute lymphocyte count (ALC) has been suggested to have a prognostic value in several subtypes of NHL. We evaluated the prognostic significance of clinical factors, including ALC, in patients with PCNSL to develop a new prognostic model. Methods We analysed prognostic factors, including ALC, at diagnosis in 81 PCNSL patients receiving high-dose methotrexate-based therapy. Results The median ALC at diagnosis was 1210 × 10 6 /L (range, 210–3610), with lymphopenia (≤875 × 10 6 /L) being detected in 27 (33.3%) patients. In the multivariate analysis, Eastern Cooperative Oncology Group performance status (ECOG PS) >1 (hazard ratio [HR] 3.18, P = 0.003), age >50 years (HR 4.23, P = 0.012), and lymphopenia at diagnosis (HR 2.83, P = 0.008) remained independent prognostic factors for low overall survival (OS). Lymphopenia was also a significant prognostic factor for progression-free survival (HR 3.17, P = 0.001). By means of a new three-factor prognostic model using ECOG PS >1, age >50 years, and presence of lymphopenia, with 1 point assigned to each factor, we successfully classified the patients into three risk groups: low (0 and 1), intermediate (2), and high (3). The 5-year OS rates of the patients in the low-, intermediate-, and high-risk groups were 74.3%, 21.7%, and 12.5%, respectively (P < 0.001). Conclusions Low ALC is a useful indicator of poor prognosis in patients with PCNSL. The proposed three-factor model should be validated in large-scale studies.

Original languageEnglish
Pages (from-to)127-135
Number of pages9
JournalEuropean Journal of Cancer
Volume57
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Lymphocyte Count
Lymphoma
Lymphopenia
Central Nervous System
Non-Hodgkin's Lymphoma
Methotrexate
Disease-Free Survival
Multivariate Analysis
Survival Rate
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Jang, Ji Eun ; Kim, Yu Ri ; Kim, Soo Jeong ; Cho, Hyunsoo ; Chung, Haerim ; Lee, Jung Yeon ; Park, Hyunsung ; Kim, Yundeok ; Cheong, June Won ; Min, Yoo Hong ; Kim, Jinseok. / A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. In: European Journal of Cancer. 2016 ; Vol. 57. pp. 127-135.
@article{27f64b901e004ce093645c3776c24e28,
title = "A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma",
abstract = "Purpose Primary central nervous system lymphoma (PCNSL) is an aggressive and rare extranodal non-Hodgkin lymphoma (NHL). Absolute lymphocyte count (ALC) has been suggested to have a prognostic value in several subtypes of NHL. We evaluated the prognostic significance of clinical factors, including ALC, in patients with PCNSL to develop a new prognostic model. Methods We analysed prognostic factors, including ALC, at diagnosis in 81 PCNSL patients receiving high-dose methotrexate-based therapy. Results The median ALC at diagnosis was 1210 × 10 6 /L (range, 210–3610), with lymphopenia (≤875 × 10 6 /L) being detected in 27 (33.3{\%}) patients. In the multivariate analysis, Eastern Cooperative Oncology Group performance status (ECOG PS) >1 (hazard ratio [HR] 3.18, P = 0.003), age >50 years (HR 4.23, P = 0.012), and lymphopenia at diagnosis (HR 2.83, P = 0.008) remained independent prognostic factors for low overall survival (OS). Lymphopenia was also a significant prognostic factor for progression-free survival (HR 3.17, P = 0.001). By means of a new three-factor prognostic model using ECOG PS >1, age >50 years, and presence of lymphopenia, with 1 point assigned to each factor, we successfully classified the patients into three risk groups: low (0 and 1), intermediate (2), and high (3). The 5-year OS rates of the patients in the low-, intermediate-, and high-risk groups were 74.3{\%}, 21.7{\%}, and 12.5{\%}, respectively (P < 0.001). Conclusions Low ALC is a useful indicator of poor prognosis in patients with PCNSL. The proposed three-factor model should be validated in large-scale studies.",
author = "Jang, {Ji Eun} and Kim, {Yu Ri} and Kim, {Soo Jeong} and Hyunsoo Cho and Haerim Chung and Lee, {Jung Yeon} and Hyunsung Park and Yundeok Kim and Cheong, {June Won} and Min, {Yoo Hong} and Jinseok Kim",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.ejca.2016.01.016",
language = "English",
volume = "57",
pages = "127--135",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

Jang, JE, Kim, YR, Kim, SJ, Cho, H, Chung, H, Lee, JY, Park, H, Kim, Y, Cheong, JW, Min, YH & Kim, J 2016, 'A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma', European Journal of Cancer, vol. 57, pp. 127-135. https://doi.org/10.1016/j.ejca.2016.01.016

A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. / Jang, Ji Eun; Kim, Yu Ri; Kim, Soo Jeong; Cho, Hyunsoo; Chung, Haerim; Lee, Jung Yeon; Park, Hyunsung; Kim, Yundeok; Cheong, June Won; Min, Yoo Hong; Kim, Jinseok.

In: European Journal of Cancer, Vol. 57, 01.04.2016, p. 127-135.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma

AU - Jang, Ji Eun

AU - Kim, Yu Ri

AU - Kim, Soo Jeong

AU - Cho, Hyunsoo

AU - Chung, Haerim

AU - Lee, Jung Yeon

AU - Park, Hyunsung

AU - Kim, Yundeok

AU - Cheong, June Won

AU - Min, Yoo Hong

AU - Kim, Jinseok

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Purpose Primary central nervous system lymphoma (PCNSL) is an aggressive and rare extranodal non-Hodgkin lymphoma (NHL). Absolute lymphocyte count (ALC) has been suggested to have a prognostic value in several subtypes of NHL. We evaluated the prognostic significance of clinical factors, including ALC, in patients with PCNSL to develop a new prognostic model. Methods We analysed prognostic factors, including ALC, at diagnosis in 81 PCNSL patients receiving high-dose methotrexate-based therapy. Results The median ALC at diagnosis was 1210 × 10 6 /L (range, 210–3610), with lymphopenia (≤875 × 10 6 /L) being detected in 27 (33.3%) patients. In the multivariate analysis, Eastern Cooperative Oncology Group performance status (ECOG PS) >1 (hazard ratio [HR] 3.18, P = 0.003), age >50 years (HR 4.23, P = 0.012), and lymphopenia at diagnosis (HR 2.83, P = 0.008) remained independent prognostic factors for low overall survival (OS). Lymphopenia was also a significant prognostic factor for progression-free survival (HR 3.17, P = 0.001). By means of a new three-factor prognostic model using ECOG PS >1, age >50 years, and presence of lymphopenia, with 1 point assigned to each factor, we successfully classified the patients into three risk groups: low (0 and 1), intermediate (2), and high (3). The 5-year OS rates of the patients in the low-, intermediate-, and high-risk groups were 74.3%, 21.7%, and 12.5%, respectively (P < 0.001). Conclusions Low ALC is a useful indicator of poor prognosis in patients with PCNSL. The proposed three-factor model should be validated in large-scale studies.

AB - Purpose Primary central nervous system lymphoma (PCNSL) is an aggressive and rare extranodal non-Hodgkin lymphoma (NHL). Absolute lymphocyte count (ALC) has been suggested to have a prognostic value in several subtypes of NHL. We evaluated the prognostic significance of clinical factors, including ALC, in patients with PCNSL to develop a new prognostic model. Methods We analysed prognostic factors, including ALC, at diagnosis in 81 PCNSL patients receiving high-dose methotrexate-based therapy. Results The median ALC at diagnosis was 1210 × 10 6 /L (range, 210–3610), with lymphopenia (≤875 × 10 6 /L) being detected in 27 (33.3%) patients. In the multivariate analysis, Eastern Cooperative Oncology Group performance status (ECOG PS) >1 (hazard ratio [HR] 3.18, P = 0.003), age >50 years (HR 4.23, P = 0.012), and lymphopenia at diagnosis (HR 2.83, P = 0.008) remained independent prognostic factors for low overall survival (OS). Lymphopenia was also a significant prognostic factor for progression-free survival (HR 3.17, P = 0.001). By means of a new three-factor prognostic model using ECOG PS >1, age >50 years, and presence of lymphopenia, with 1 point assigned to each factor, we successfully classified the patients into three risk groups: low (0 and 1), intermediate (2), and high (3). The 5-year OS rates of the patients in the low-, intermediate-, and high-risk groups were 74.3%, 21.7%, and 12.5%, respectively (P < 0.001). Conclusions Low ALC is a useful indicator of poor prognosis in patients with PCNSL. The proposed three-factor model should be validated in large-scale studies.

UR - http://www.scopus.com/inward/record.url?scp=84978993744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978993744&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2016.01.016

DO - 10.1016/j.ejca.2016.01.016

M3 - Article

C2 - 26918738

AN - SCOPUS:84978993744

VL - 57

SP - 127

EP - 135

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -